174 related articles for article (PubMed ID: 23361053)
21. Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1.
Zhang Y; Akinmade D; Hamburger AW
Cancer Lett; 2008 Jul; 265(2):298-306. PubMed ID: 18355957
[TBL] [Abstract][Full Text] [Related]
22. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.
Kok M; Zwart W; Holm C; Fles R; Hauptmann M; Van't Veer LJ; Wessels LF; Neefjes J; Stål O; Linn SC; Landberg G; Michalides R
Breast Cancer Res Treat; 2011 Jan; 125(1):1-12. PubMed ID: 20213082
[TBL] [Abstract][Full Text] [Related]
23. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.
Hamburger AW
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):225-33. PubMed ID: 18425425
[TBL] [Abstract][Full Text] [Related]
24. Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells.
Arias-Romero LE; Villamar-Cruz O; Huang M; Hoeflich KP; Chernoff J
Cancer Res; 2013 Jun; 73(12):3671-82. PubMed ID: 23576562
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
[TBL] [Abstract][Full Text] [Related]
26. Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity.
Rayala SK; Molli PR; Kumar R
Cancer Res; 2006 Jun; 66(12):5985-8. PubMed ID: 16778166
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
29. The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines.
Ergun S; Tayeb TS; Arslan A; Temiz E; Arman K; Safdar M; Dağlı H; Korkmaz M; Nacarkahya G; Kırkbeş S; Oztuzcu S
Gene; 2015 Jan; 555(2):377-81. PubMed ID: 25447917
[TBL] [Abstract][Full Text] [Related]
30. ErbB3-binding protein EBP1 decreases ErbB2 levels via a transcriptional mechanism.
Ghosh A; Awasthi S; Hamburger AW
Oncol Rep; 2013 Mar; 29(3):1161-6. PubMed ID: 23242156
[TBL] [Abstract][Full Text] [Related]
31. P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation.
Rayala SK; Talukder AH; Balasenthil S; Tharakan R; Barnes CJ; Wang RA; Aldaz CM; Khan S; Kumar R
Cancer Res; 2006 Feb; 66(3):1694-701. PubMed ID: 16452229
[TBL] [Abstract][Full Text] [Related]
32. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
[TBL] [Abstract][Full Text] [Related]
35. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
36. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
37. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
[TBL] [Abstract][Full Text] [Related]
38. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines.
van Agthoven T; Godinho MF; Wulfkuhle JD; Petricoin EF; Dorssers LC
Int J Cancer; 2012 Nov; 131(9):1998-2007. PubMed ID: 22328489
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
